Sandoz opens new antibiotic and biosimilar facilities in Austria and Germany
Antimicrobial resistance is considered one of the top ten global public health threats
Read More
Tag: Sandoz
Sandoz’s Tyruko biosimilar granted FDA approval to treat relapsing MS
The disease-modifying therapy is approved to treat all indications covered by Tysabri
Read More
Sandoz launches new global health inequalities initiative
‘Act4Biosimilars’ will improve patient access and increase adoption in over 30 countries by 2030
Read More
Novartis recruits GSK exec as new Sandoz CEO
Former Sandoz head Richard Francis stepped down in March amid the division’s ongoing transformation.
Read More
NHS set to save record £300 million on highest drug spend
The NHS is set to save a record £300 million after negotiating deals with five manufacturers on low-cost versions of the health service’s most costly drug.
Read More
Sandoz dumps US filing for biosimilar rituximab
Novartis group Sandoz has decided not to pursue US submission of a biosimilar version of Roche’s Rituxan/Mabthera, after a request from regulators for more data.
Read More
Sandoz launches second digital health competition
Novartis’ generics arm Sandoz has launched the second Healthcare Access Challenge (HACk), which is looking to support digital solutions to local healthcare access challenges.
Read More
Novartis to sell Sandoz assets to Aurobindo for $900m
Novartis is selling parts of its generics business Sandoz to Aurobindo in a deal worth at least $900 million.
Read More
EU nod for Sandoz’ Remicade biosimilar Zessly
The European Commission has green-lighted Novartis unit Sandoz’ Zessly, a biosimilar version of Johnson & Johnson and Merck & Co’s Remicade
Read More
Six new therapies backed for EU approval
Six medicines have taken a big step towards European approval having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
Sandoz and Biocon to jointly develop ‘multiple’ biosimilars
Novartis’ Sandoz has formed a global partnership with Biocon to develop, manufacture and commercialise multiple biosimilars in immunology and oncology.
Read More
EU regulators to review Sandoz’ Neulasta biosimilar
The European Medicines Agency has accepted for review Novartis unit Sandoz’ biosimilar of Amgen’s Neulasta.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
